ArticleJACS Au2026
Skeletal Editing of Isoxazoles to Pyrimidines via O‑to-CN Transmutation.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterocyclic scaffolds are highly valued in medicinal chemistry due to their structural rigidity, tunable electronic properties, and functional versatility. The direct interconversion of heterocyclic cores via skeletal editing provides rapid access to structurally diverse bioactive molecules. Herein, we report a Ru-catalyzed ring expansion strategy that converts isoxazoles into pyrimidines via O-to-CN transmutation. The transformation employs readily available nitriles as the CN source and proceeds via ruthenium-catalyzed N-O bond cleavage to generate an enaminone intermediate, followed by nucleophilic addition and cyclization. This protocol accommodates a broad range of functional groups and enables the late-stage modification of complex pharmaceuticals, including receptor modulators and anticancer agents. This skeletal editing strategy expands the synthetic toolbox for medicinal chemistry and scaffold diversification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.